# Fasting Study of Alprazolam Extended-Release Tablets 3 mg to Xanax XR® Tablets 3 mg

> **NCT00647634** · PHASE1 · COMPLETED · sponsor: **Mylan Pharmaceuticals Inc** · enrollment: 21 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Alprazolam Extended-Release Tablets 3 mg
- **DRUG:** Xanax XR® Tablets (3 mg

## Key facts

- **NCT ID:** NCT00647634
- **Lead sponsor:** Mylan Pharmaceuticals Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-08
- **Primary completion:** 2004-08
- **Final completion:** 2004-08
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2024-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00647634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00647634, "Fasting Study of Alprazolam Extended-Release Tablets 3 mg to Xanax XR® Tablets 3 mg". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00647634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*